Zilver PTX Drug-Eluting Peripheral Stent Post-Approval Study
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral vascular disorders
- Focus Therapeutic Use
- 13 Feb 2017 Planned End Date changed from 1 Apr 2021 to 1 Oct 2021.
- 24 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Nov 2013 New trial record